PropertyValue
?:abstract
  • BACKGROUND: Active cancer, immunosuppressive treatments and immunotherapies have been reported to increase cancer patients’ risk of developing severe COVID-19 infection. For patients and clinicians, treatment risk must be weighed against disease progression. METHODS: This retrospective case series surveys urological cancer patients who made informed decisions to continue anticancer treatment (ACT) at one centre from March to June 2020. RESULTS: Sixty-one patients (44 bladder, 10 prostate, 7 upper urinary tract cancers) received 195 cycles of ACT (99 chemotherapy, 59 immunotherapy, 37 as part of ongoing clinical trials), with a range of indications: 43 palliative, 10 neoadjuvant, 8 adjuvant. One patient tested positive for COVID-19 but experienced only mild symptoms. Fourteen patients interrupted treatment outside of their schedule, seven of these due to potential COVID-19 associated risk. ACT supportive steroids were not associated with higher rates of COVID-19. CONCLUSIONS: This single-centre series reports that ACT administration did not result in an apparent excess in symptomatic COVID-19 infections.
?:creator
?:doi
  • 10.1038/s41416-021-01263-7
?:doi
?:journal
  • Br_J_Cancer
?:license
  • cc-by
?:pmc_json_files
  • document_parses/pmc_json/PMC7869760.xml.json
?:pmcid
?:pmid
?:pmid
  • 33558714.0
?:publication_isRelatedTo_Disease
?:source
  • Medline; PMC
?:title
  • Urological cancer patients receiving treatment during COVID-19: a single-centre perspective
?:type
?:year
  • 2021-02-08

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/mixpcamx>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/mixpcamx>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all